Rigel Pharmaceuticals Inc.
Organization details
- Legal name
- Rigel Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RIGL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001034842
- EIN
- 94-3248524
Board of directors
-
Alison L. Hannah · DirectorSince 2023
-
Anthony Gregg Lapointe · DirectorSince 2023
-
Brian L. Kotzin · DirectorSince 2023
-
Gary A. Lyons · DirectorSince 2023
-
Jane Wasman · DirectorSince 2023
-
Kamil Ali-Jackson · DirectorSince 2023
-
Mark W. Frohlich · DirectorSince 2025
-
Michael Patrick Miller · DirectorSince 2026
-
Raul R. Rodriguez · Director · CEO, PresidentSince 2023
-
Walter H. Moos · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.2%
-
97.7%
-
98.2%
Board connections
7 of this board's directors also sit on 9 other boards. 8 are in the same sector.
-
Eledon Pharmaceuticals Inc. Same sectorvia Gary A. Lyons
-
Kyverna Therapeutics Inc. Same sectorvia Brian L. Kotzin
- via Alison L. Hannah
-
Neurocrine Biosciences Inc. Same sectorvia Gary A. Lyons
-
PDS Biotechnology Corporation Same sectorvia Kamil Ali-Jackson
-
Puma Biotechnology Inc Same sectorvia Michael Patrick Miller
-
SELLAS Life Sciences Group Inc. Same sectorvia Jane Wasman
-
Soligenix Inc. Same sectorvia Anthony Gregg Lapointe
-
Travere Therapeutics Inc. Same sectorvia Gary A. Lyons
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $305,865
- 3 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +694 | $12.70 | $8,814 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +620 | $18.70 | $11,594 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +2,000 | $24.20 | $48,400 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +1,286 | $24.20 | $31,121 |
| Sep 1, 2026 | Furey Raymond J. Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for tax | −877 | $47.50 | $41,658 |
| Sep 1, 2026 | Raul R. Rodriguez Director, Officer (CEO, President) | Shares withheld for tax | −2,424 | $47.50 | $115,140 |
| Sep 1, 2026 | Santos David A Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −874 | $47.50 | $41,515 |
| Sep 1, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Shares withheld for tax | −928 | $47.50 | $44,080 |
| Jul 8, 2026 | Alison L. Hannah Officer (EVP, Chief Medical Officer) | Grant or award | +24,400 | — | — |
| Jun 22, 2026 | Kamil Ali-Jackson Director | Open-market sale | −2,500 | $35.00 | $87,500 |
| Jun 1, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +1,200 | $18.70 | $22,440 |
| Jun 1, 2026 | Santos David A Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −874 | $29.86 | $26,098 |
| Jun 1, 2026 | Rojkjaer Lisa Officer (EVP, Chief Medical Officer) | Shares withheld for tax | −850 | $29.86 | $25,381 |
| Jun 1, 2026 | Raul R. Rodriguez Director, Officer (CEO, President) | Shares withheld for tax | −2,424 | $29.86 | $72,381 |
| Jun 1, 2026 | Furey Raymond J. Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for tax | −877 | $29.86 | $26,187 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Rigel Pharmaceuticals Inc.
Who is the CEO of Rigel Pharmaceuticals Inc.?
Raul R. Rodriguez is Rigel Pharmaceuticals Inc.'s CEO, President.
How many directors are on Rigel Pharmaceuticals Inc.'s board?
Rigel Pharmaceuticals Inc.'s board has 10 directors: Alison L. Hannah, Anthony Gregg Lapointe, Brian L. Kotzin, Gary A. Lyons, Jane Wasman, Kamil Ali-Jackson, Mark W. Frohlich, Michael Patrick Miller, Raul R. Rodriguez and Walter H. Moos.
Are Rigel Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Rigel Pharmaceuticals Inc. insiders made no open-market purchases and sold $305,865 of shares in 3 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="rigel-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.